JP2022525661A5 - - Google Patents

Info

Publication number
JP2022525661A5
JP2022525661A5 JP2021556442A JP2021556442A JP2022525661A5 JP 2022525661 A5 JP2022525661 A5 JP 2022525661A5 JP 2021556442 A JP2021556442 A JP 2021556442A JP 2021556442 A JP2021556442 A JP 2021556442A JP 2022525661 A5 JP2022525661 A5 JP 2022525661A5
Authority
JP
Japan
Prior art keywords
fusion protein
seq
sequence
amino acid
protein according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021556442A
Other languages
English (en)
Japanese (ja)
Other versions
JP7600135B2 (ja
JP2022525661A (ja
Filing date
Publication date
Priority claimed from EP19163970.7A external-priority patent/EP3711772A1/en
Application filed filed Critical
Publication of JP2022525661A publication Critical patent/JP2022525661A/ja
Publication of JP2022525661A5 publication Critical patent/JP2022525661A5/ja
Application granted granted Critical
Publication of JP7600135B2 publication Critical patent/JP7600135B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021556442A 2019-03-20 2020-03-20 組換えccnドメインタンパク質および融合タンパク質 Active JP7600135B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19163970.7A EP3711772A1 (en) 2019-03-20 2019-03-20 Recombinant proteins and fusion proteins
EP19163970.7 2019-03-20
PCT/EP2020/057773 WO2020188081A1 (en) 2019-03-20 2020-03-20 Recombinant ccn domain proteins and fusion proteins

Publications (3)

Publication Number Publication Date
JP2022525661A JP2022525661A (ja) 2022-05-18
JP2022525661A5 true JP2022525661A5 (https=) 2023-03-28
JP7600135B2 JP7600135B2 (ja) 2024-12-16

Family

ID=66102364

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556442A Active JP7600135B2 (ja) 2019-03-20 2020-03-20 組換えccnドメインタンパク質および融合タンパク質

Country Status (12)

Country Link
US (1) US12606602B2 (https=)
EP (2) EP3711772A1 (https=)
JP (1) JP7600135B2 (https=)
KR (1) KR20210142681A (https=)
CN (1) CN113747912B (https=)
AU (1) AU2020243073B2 (https=)
BR (1) BR112021017147A2 (https=)
CA (1) CA3133740A1 (https=)
IL (1) IL285930B2 (https=)
MX (1) MX2021011407A (https=)
SG (1) SG11202109738QA (https=)
WO (1) WO2020188081A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023552810A (ja) * 2020-12-08 2023-12-19 シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) 抗egfrキメラ抗原受容体
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease
GB202400055D0 (en) * 2024-01-03 2024-02-14 Tribune Therapeutics Ab Use of ccn domain-containing proteins for the treatment of disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
GB8909916D0 (en) 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1999047556A2 (en) * 1998-03-19 1999-09-23 Trustees Of Tufts College Novel heparin-induced ccn-like molecules and uses therefor
EP1326980B1 (en) * 2000-10-16 2008-03-19 Genentech, Inc. Methods of treatment using wisp polypeptides
CN1835763B (zh) 2003-06-20 2011-04-20 妙甯公司 Ccn1组合物和方法
FR2858234B1 (fr) 2003-08-01 2007-09-14 Centre Nat Rech Scient Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers
EP1771467A2 (en) 2004-07-26 2007-04-11 Asterion Limited Linkers
ATE506961T1 (de) * 2005-01-10 2011-05-15 Univ Rosalind Franklin Medicine & Science Ccn3 proteine zur behandlung und diagnose von nierenerkrankungen
CN101146826A (zh) 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
EP2015781A4 (en) * 2005-09-12 2009-12-23 Univ Johns Hopkins COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF
JP2009067678A (ja) * 2005-12-07 2009-04-02 Nihon Nosan Kogyo Kk 結合組織増殖因子に対する抗体又はそれを含む組成物
US20080207489A1 (en) 2007-02-21 2008-08-28 John Castellot Use of CCN5 for treatment of smooth muscle proliferation disorders
WO2009086132A2 (en) 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
DK3061817T3 (en) * 2009-04-30 2019-03-04 Kao Corp Alkaline protease variants
TW201102086A (en) 2009-06-04 2011-01-16 Hoffmann La Roche Antibodies against human CCN1 and uses thereof
JP5820378B2 (ja) * 2009-09-09 2015-11-24 ファーマイン コーポレーションPharmain Corporation 治療剤の送達のための陰イオンコア組成物およびその製造ならびに使用方法
MX340971B (es) 2009-11-23 2016-08-02 Amgen Inc * Fragmento cristalizable (fc) de anticuerpo monomerico.
KR101187814B1 (ko) 2010-03-22 2012-10-08 광주과학기술원 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법
JP5939584B2 (ja) 2010-04-02 2016-06-22 ロザリンド フランクリン ユニバーシティー オブ メディスン アンド サイエンス 治療用ccn3ペプチドおよびそれらの類似体
US9114112B2 (en) * 2010-04-02 2015-08-25 Rosalind Franklin University Of Medicine And Science CCN3 and CCN3 peptides and analogs thereof for therapeutic uses
PT2621515T (pt) * 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
ES2623912T3 (es) 2010-12-23 2017-07-12 Janssen Biotech, Inc. Mutantes FC de anticuerpo activo resistente a proteasa
WO2014008582A1 (en) 2012-07-11 2014-01-16 The University Of Western Ontario Method of treating wounds with penostin and/or ccn2
US20140271641A1 (en) 2013-03-14 2014-09-18 University Of Guelph Thrombospondin-1 polypeptides and methods of using same
GB201316592D0 (en) 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
AU2016228806B2 (en) 2015-03-12 2020-10-22 Medimmune, Llc Method of purifying albumin-fusion proteins
JP2018517708A (ja) 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
GB201512733D0 (en) 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
CN105396136B (zh) * 2015-11-23 2018-10-30 上海交通大学医学院附属第九人民医院 CCN1(Cyr61)在治疗皮肤损伤及皮肤萎缩相关疾病中的应用
EP3192806A1 (en) 2016-01-13 2017-07-19 Affiris AG Alpha chain of the high-affinity ige receptor (fceria)
CA3011887C (en) 2016-03-14 2024-10-29 Universitetet I Oslo Genetically transformed immunoglobulins with altered FCRN binding
US10028906B2 (en) 2016-03-22 2018-07-24 Rosalind Franklin University Of Medicine And Science Method and kit for treating a solid tumor and associated desmoplasia
US11795202B2 (en) 2016-08-04 2023-10-24 Stichting Vumc Fusion polypeptide comprising a foreign antigen and self antigen
US20180127478A1 (en) 2016-09-16 2018-05-10 Wei-Chiang Shen SINGLE CHAIN Fc-DIMER-HUMAN GROWTH HORMONE FUSION PROTEIN FOR IMPROVED DRUG DELIVERY
KR20180099537A (ko) * 2017-02-28 2018-09-05 주식회사 파이안바이오테크놀로지 근섬유모세포의 병리적 활성이 초래하는 섬유증식성 질병 치료제
KR102008407B1 (ko) 2017-09-05 2019-08-08 한국생명공학연구원 코돈 최적화된 il-21 및 이의 용도
WO2019071007A1 (en) 2017-10-05 2019-04-11 New York Genome Center, Inc. METHODS AND COMPOSITIONS FOR TARGETING VASCULAR MIMETTISM

Similar Documents

Publication Publication Date Title
US20240368236A1 (en) Growth differentiation factor 15 (gdf-15) constructs
JP7128246B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2021510162A5 (https=)
JP2022525661A5 (https=)
JP2018171063A5 (https=)
CN114206908B (zh) 具有改善的稳定性的经设计的锚蛋白重复结构域
RU2006146995A (ru) Химерные белки, ингибирующие ангиогенез, и их применение
CN100390201C (zh) 具有增强红细胞生成素体内活性的融合蛋白
WO1990013306A2 (en) Small polypeptides
ES3011833T3 (en) Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
JP2015504052A5 (https=)
JP2010504336A5 (https=)
JP2023179752A5 (https=)
WO2018077098A1 (zh) 一种用于治疗肠道疾病的融合蛋白
CN103641896A (zh) 明胶样单元的用途
Kuo et al. Orientation of type VI collagen monomers in molecular aggregates
WO2023280133A1 (zh) 融合蛋白及其应用
JP2020518613A5 (https=)
JP2022532445A (ja) 新規な中間体製造による持続型薬物結合体の製造方法
CN118076373A (zh) 用于联合疗法的包括生长分化因子-15变体和胰高血糖素样肽-1受体激动剂的组合物
JP2024543158A5 (https=)
JP2017501970A (ja) 薬学的活性エンティティのマルチサブユニット構造への標的特異的送達のためのマルチサブユニット構造のサブユニットの結合ドメインの使用
RU2021125671A (ru) Рекомбинантные белки с доменами ccn и слитые белки
TWI857985B (zh) 胜肽之結合物及其製造方法
US20200031895A1 (en) Stabilized proteolytically activated growth differentiation factor 11